Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Onto better TRAILs for cancer treatment.

de Miguel D, Lemke J, Anel A, Walczak H, Martinez-Lostao L.

Cell Death Differ. 2016 May;23(5):733-47. doi: 10.1038/cdd.2015.174. Epub 2016 Mar 4. Review.

2.

TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2.

Tamada T, Shinmi D, Ikeda M, Yonezawa Y, Kataoka S, Kuroki R, Mori E, Motoki K.

Sci Rep. 2015 Dec 17;5:17936. doi: 10.1038/srep17936.

3.

Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia.

Bruzzoni-Giovanelli H, González JR, Sigaux F, Villoutreix BO, Cayuela JM, Guilhot J, Preudhomme C, Guilhot F, Poyet JL, Rousselot P.

Oncotarget. 2015 Nov 3;6(34):36269-77. doi: 10.18632/oncotarget.5915.

4.

Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines.

Polanski R, Vincent J, Polanska UM, Petreus T, Tang EK.

Cell Death Dis. 2015 Oct 1;6:e1893. doi: 10.1038/cddis.2015.234.

5.

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.

Huet HA, Growney JD, Johnson JA, Li J, Bilic S, Ostrom L, Zafari M, Kowal C, Yang G, Royo A, Jensen M, Dombrecht B, Meerschaert KR, Kolkman JA, Cromie KD, Mosher R, Gao H, Schuller A, Isaacs R, Sellers WR, Ettenberg SA.

MAbs. 2014;6(6):1560-70. doi: 10.4161/19420862.2014.975099.

6.

Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.

Bychkov ML, Gasparian ME, Dolgikh DA, Kirpichnikov MP.

PLoS One. 2014 Oct 13;9(10):e109756. doi: 10.1371/journal.pone.0109756. eCollection 2014.

7.

Getting TRAIL back on track for cancer therapy.

Lemke J, von Karstedt S, Zinngrebe J, Walczak H.

Cell Death Differ. 2014 Sep;21(9):1350-64. doi: 10.1038/cdd.2014.81. Epub 2014 Jun 20. Review.

8.

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.

Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, Gabrilovich DI.

J Clin Invest. 2014 Jun;124(6):2626-39. doi: 10.1172/JCI74056. Epub 2014 May 1.

9.

Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.

Neumann S, Hasenauer J, Pollak N, Scheurich P.

J Biol Chem. 2014 Jun 6;289(23):16576-87. doi: 10.1074/jbc.M114.559468. Epub 2014 Apr 24.

10.

Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.

Pavet V, Shlyakhtina Y, He T, Ceschin DG, Kohonen P, Perälä M, Kallioniemi O, Gronemeyer H.

Cell Death Dis. 2014 Jan 30;5:e1043. doi: 10.1038/cddis.2014.5.

11.

Apoptosis-associated uncoupling of bone formation and resorption in osteomyelitis.

Marriott I.

Front Cell Infect Microbiol. 2013 Dec 19;3:101. doi: 10.3389/fcimb.2013.00101. eCollection 2013. Review.

12.

Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma.

Koschny R, Brost S, Hinz U, Sykora J, Batke EM, Singer S, Breuhahn K, Stremmel W, Walczak H, Schemmer P, Schirmacher P, Ganten TM.

BMC Cancer. 2013 Nov 9;13:532. doi: 10.1186/1471-2407-13-532.

13.

High molecular weight complex analysis of Epstein-Barr virus Latent Membrane Protein 1 (LMP-1): structural insights into LMP-1's homo-oligomerization and lipid raft association.

Wrobel CM, Geiger TR, Nix RN, Robitaille AM, Weigand S, Cervantes A, Gonzalez M, Martin JM.

Virus Res. 2013 Dec 26;178(2):314-27. doi: 10.1016/j.virusres.2013.09.025. Epub 2013 Sep 25.

14.

Epigonal conditioned media from bonnethead shark, Sphyrna tiburo, induces apoptosis in a T-cell leukemia cell line, Jurkat E6-1.

Walsh CJ, Luer CA, Yordy JE, Cantu T, Miedema J, Leggett SR, Leigh B, Adams P, Ciesla M, Bennett C, Bodine AB.

Mar Drugs. 2013 Aug 26;11(9):3224-57. doi: 10.3390/md11093224.

15.

Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.

Bremer E.

ISRN Oncol. 2013 Jun 11;2013:371854. doi: 10.1155/2013/371854. Print 2013.

16.

Mesenchymal stem cells as vectors for lung cancer therapy.

Kolluri KK, Laurent GJ, Janes SM.

Respiration. 2013;85(6):443-51. doi: 10.1159/000351284. Epub 2013 May 23. Review.

17.

Cysteine-rich domain 1 of CD40 mediates receptor self-assembly.

Smulski CR, Beyrath J, Decossas M, Chekkat N, Wolff P, Estieu-Gionnet K, Guichard G, Speiser D, Schneider P, Fournel S.

J Biol Chem. 2013 Apr 12;288(15):10914-22. doi: 10.1074/jbc.M112.427583. Epub 2013 Mar 5.

18.

The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity.

Neumann S, Bidon T, Branschädel M, Krippner-Heidenreich A, Scheurich P, Doszczak M.

PLoS One. 2012;7(8):e42526. doi: 10.1371/journal.pone.0042526. Epub 2012 Aug 3.

19.

Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.

Qiao C, Hu M, Guo L, Lv M, Lin Z, Geng J, Lang X, Li X, Li Y, Ma Y, Feng J, Shen B.

BMC Immunol. 2012 Jul 12;13:40. doi: 10.1186/1471-2172-13-40.

20.

Microarray analysis of gene expression in West Nile virus-infected human retinal pigment epithelium.

Munoz-Erazo L, Natoli R, Provis JM, Madigan MC, King NJ.

Mol Vis. 2012;18:730-43. Epub 2012 Mar 27.

Items per page

Supplemental Content

Write to the Help Desk